Email this article Correlation of HbA1c and postprandial glycemia during a standard breakfast test in patients with type 2 diabetes receiving glibenclamide
- Authors: Dreval AV1, Cheporeva ON1, Redkin Y.A1, Misnikova IV1
-
Affiliations:
- M. F. Vladimirsky Moscow Regional Research Clinical Institute
- Issue: Vol 82, No 8 (2010)
- Pages: 41-44
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30635
- ID: 30635
Cite item
Full Text
Abstract
Aim. To analyze the effect of glibenclamide on carbohydrate metabolic parameters, glucose values after standard breakfast in particular, in patients with type 2 diabetes (T2D).
Subjects and methods. Thirty patients aged 57.6±9.4 years with a 4.4±4.0-year history of T2D received glibenclamide in a daily dose of 10.9±4.4 mg in combination with diet therapy for 3 months. Venous plasma glycemia was determined before and at the end of the fasting test, 60 and 120 minutes after a standard breakfast test.
The area under the glycemic curve was calculated using the trapezoidal method during the standard breakfast test. Out of all possible formulas reflecting a blood glucose increase in relative values during the test, there were two most acceptable formulas that were chosen for further calculations: 1) the contribution of postprandial glycemia exceeding fasting glycemia to postprandial glycemia exceeding 6.1 mmol/l (OS1/2); 2) that of postprandial glycemia exceeding the glycemia of 6.1 mmol/l to postprandial glycemia in the standard breakfast test (OS2/S).
Results. Follow 3-month therapy, glycated hemoglobin (HBA1c) decreased from 8.7±1.8 to 7.0±1.0% (p < 0.0001), fasting plasma glucose reduced from 9.8±2.7 to 8.3+-1.7 mmol/l (p < 0.01); it decreased from 14.8±3.9 to 13.2+-3.3 mmol/l (p < 0.01) and from 13.3±3.6 to 11.1+-3.0 mmol/l (p < 0.02) 1 and 2 hours after the load test, respectively. There was a significant reduction in the total area under the glycemic curve (S) - from 1583.5±405.8 to 1375.7+-320.1 mmol/lmin. However, there were no significant changes. There was a significant increase in the relative value OS1/2 from 51.7±17.7 to 62.8±20.0% and a significant reduction in OS2/S. Analysis of the area in relative values (OS1/2 and OS2/S) obviates the ambiguousness of the results obtained when analyzing the area in absolute values.
Conclusion. Glibenclamide treatment causes a statistically significant reduction in fasting and postprandial plasma glucose levels, glycated hemoglobin, and relative area values during the standard breakfast test.
Subjects and methods. Thirty patients aged 57.6±9.4 years with a 4.4±4.0-year history of T2D received glibenclamide in a daily dose of 10.9±4.4 mg in combination with diet therapy for 3 months. Venous plasma glycemia was determined before and at the end of the fasting test, 60 and 120 minutes after a standard breakfast test.
The area under the glycemic curve was calculated using the trapezoidal method during the standard breakfast test. Out of all possible formulas reflecting a blood glucose increase in relative values during the test, there were two most acceptable formulas that were chosen for further calculations: 1) the contribution of postprandial glycemia exceeding fasting glycemia to postprandial glycemia exceeding 6.1 mmol/l (OS1/2); 2) that of postprandial glycemia exceeding the glycemia of 6.1 mmol/l to postprandial glycemia in the standard breakfast test (OS2/S).
Results. Follow 3-month therapy, glycated hemoglobin (HBA1c) decreased from 8.7±1.8 to 7.0±1.0% (p < 0.0001), fasting plasma glucose reduced from 9.8±2.7 to 8.3+-1.7 mmol/l (p < 0.01); it decreased from 14.8±3.9 to 13.2+-3.3 mmol/l (p < 0.01) and from 13.3±3.6 to 11.1+-3.0 mmol/l (p < 0.02) 1 and 2 hours after the load test, respectively. There was a significant reduction in the total area under the glycemic curve (S) - from 1583.5±405.8 to 1375.7+-320.1 mmol/lmin. However, there were no significant changes. There was a significant increase in the relative value OS1/2 from 51.7±17.7 to 62.8±20.0% and a significant reduction in OS2/S. Analysis of the area in relative values (OS1/2 and OS2/S) obviates the ambiguousness of the results obtained when analyzing the area in absolute values.
Conclusion. Glibenclamide treatment causes a statistically significant reduction in fasting and postprandial plasma glucose levels, glycated hemoglobin, and relative area values during the standard breakfast test.
About the authors
A V Dreval
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Email: Dreval@diabet.ru
M. F. Vladimirsky Moscow Regional Research Clinical Institute
O N Cheporeva
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Email: tcolga@yandex.ru
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Yu A Redkin
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Email: yuriy-redkin@mtu-net.ru
M. F. Vladimirsky Moscow Regional Research Clinical Institute
I V Misnikova
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Email: inna-misnikova@mail.ru
M. F. Vladimirsky Moscow Regional Research Clinical Institute
References
- Paolisso G., Rizzo M. R., Barbieri M. et al. Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions. Diabet. Metab. 2003; 1 (1): 335-340.
- Temelkova-Kurktschiev T. S., Koehler C., Henkel E. et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbAlc level. Diabet. Care 2000; 23 (12): 1830-1834.
- Breuer H. W. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int. J. Clin. Pharmacol. Ther. 2003; 41 (10): 421-440.
- Древаль А. В., Редькин Ю. А., Богомолов В. В. Сравнительная оценка методов математической обработки результатов стандартного перорального теста толерантности к глюкозе. Пробл. эндокринол. 2007; 53 (1): ХХ-ХХ.
- Древаль А. В., Редькин Ю. А., Богомолов В. В. Корреляция уровня НbА1с и постпрандиальной гликемии в пероральном тесте толерантности к глюкозе у больных сахарным диабетом 2-го типа. Пробл. эндокринол. - 2007; 53 (1): 10-18.
- Древаль А. В., Редькин Ю. А., Богомолов В. В. Динамика постпрандиальной гликемии, массы тела и сердечно-сосудистых показателей на фоне монотерапии метформином больных сахарным диабетом 2-го типа. Пробл. эндокринол. 2007; 53 (1): 18-25.
- Редькин Ю. А., Древаль А. В., Богомолов В. В. Эффект орлистата на постпрандиальную гликемию в ПТТГ и другие метаболические параметры у больных сахарным диабетом 2-го типа. Пробл. эндокринол. 2007; 53 (4): 7-11.
- Dreval A. V., Redkin J. A., Bogomolov V. V. Correlation between HbA1c level and OGTT parameters in type 2 diabetic patients. In: The World congress on CODHy, Oct. 26-29, 2006, Berlin, Germany.
- Monnier L., Colette C., Rabasa-Lhoret R. et al. Morning hyperglycemic excursions. Diabet. Care 2002; 25: 737-741.
Supplementary files
